Patients who received either dose of abelacimab had a significantly lower risk for the primary outcome than those who received rivaroxaban, both among those aged 75 years or older (90 mg: hazard ratio ...
OCEANIC-STROKE randomized 12,327 patients within 72 hours of noncardioembolic stroke or high-risk TIA to asundexian 50 mg daily versus placebo atop single or dual antiplatelet therapy. A 26% relative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results